European Organisation for Rare Diseases

Last updated
European Organisation for Rare Diseases
Established1997
President
Yann Le Cam

EURORDIS-Rare Diseases Europe (EURORDIS) is a non-governmental patient-driven alliance of patient organisations and individuals active in the field of rare diseases that promotes research on rare diseases and commercial development of orphan drugs. EURORDIS is dedicated to improving the quality of life of all people living with rare diseases in Europe. It was founded in 1997; it is supported by its members and by the French Muscular Dystrophy Association (AFM), the European Commission, corporate foundations and the health industry. [1]

Contents

There are an estimated 20–30 million people living with rare diseases in Europe alone, [2] and an estimated 6,000 rare diseases. EURORDIS represents more than 960 rare disease organisations in 63 different countries (of which 26 are EU member states), covering more than 2,000 rare diseases. [1]

EURORDIS is a development of the patient self-advocacy movement, itself widely attributed to AIDS activism. [3]

EURORDIS was the founding partner of Rare Disease Day in 2008 and remains its lead coordinator. [4] To foster awareness for the Rare Disease Day, EURORDIS organises the EURORDIS Black Pearl Awards each year. [5]

National organisations with a similar focus include National Organization for Rare Disorders (NORD) in the United States, Canadian Organization for Rare Disorders (CORD) in Canada, [6] Organization for Rare Diseases India (ORDI) in India, Allianz Chronischer Seltener Erkrankungen  [ de ] (ACHSE) in Germany, and Federación Española de Enfermedades Raras (FEDER) in Spain. [2]

See also

Related Research Articles

Canavan disease, or Canavan–Van Bogaert–Bertrand disease, is a rare and fatal autosomal recessive degenerative disease that causes progressive damage to nerve cells and loss of white matter in the brain. It is one of the most common degenerative cerebral diseases of infancy. It is caused by a deficiency of the enzyme aminoacylase 2, and is one of a group of genetic diseases referred to as leukodystrophies. It is characterized by degeneration of myelin in the phospholipid layer insulating the axon of a neuron and is associated with a gene located on human chromosome 17.

<span class="mw-page-title-main">Glycogen storage disease</span> Medical condition

A glycogen storage disease is a metabolic disorder caused by a deficiency of an enzyme or transport protein affecting glycogen synthesis, glycogen breakdown, or glucose breakdown, typically in muscles and/or liver cells.

A rare disease is a disease that affects a small percentage of the population. In some parts of the world, the term orphan disease describes a rare disease whose rarity results in little or no funding or research for treatments, without financial incentives from governments or other agencies. Orphan drugs are medications targeting orphan diseases.

Rheumatology is a branch of medicine devoted to the diagnosis and management of disorders whose common feature is inflammation in the bones, muscles, joints, and internal organs. Rheumatology covers more than 100 different complex diseases, collectively known as rheumatic diseases, which includes many forms of arthritis as well as lupus and Sjögren's syndrome. Doctors who have undergone formal training in rheumatology are called rheumatologists.

An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by the conditions. The conditions that orphan drugs are used to treat are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy that depends on the legislation of the country.

<span class="mw-page-title-main">Hereditary angioedema</span> Disorder resulting in severe swelling

Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling. The swelling most commonly affects the arms, legs, face, intestinal tract, and airway. If the intestinal tract is affected, abdominal pain and vomiting may occur. Swelling of the airway can result in its obstruction and trouble breathing. Without preventive treatment, attacks typically occur every two weeks and last for a few days.

<span class="mw-page-title-main">Disorders of sex development</span> Medical conditions involving the development of the reproductive system

Disorders of sex development (DSDs), also known as variations in sex characteristics (VSC), are congenital conditions affecting the reproductive system, in which development of chromosomal, gonadal, or anatomical sex is atypical.

<span class="mw-page-title-main">CSL Behring</span>

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.

Orphanet is an organisation and knowledge base dedicated to rare diseases as well as corresponding diagnosis, orphan drugs, clinical trials and expert networks.

Primary hyperoxaluria is a rare condition, resulting in increased excretion of oxalate, with oxalate stones being common.

<span class="mw-page-title-main">National Organization for Rare Disorders</span> U.S. nonprofit organization

The National Organization for Rare Disorders (NORD) is an American non-profit organization aiming to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers. It was founded in 1983 by Abbey Meyers, along with individuals and rare diseases leaders of rare disease support groups, and it is a 501(c)(3) tax exempt organization.

<span class="mw-page-title-main">Rare Disease Day</span> Observance to raise awareness for rare diseases

Rare Disease Day is an observance held on the last day of February to raise awareness for rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families. The date is chosen because in leap years it is February 29, the rarest date. The European Organisation for Rare Diseases established the day in 2008 to raise awareness for unknown or overlooked illnesses. According to that organization, treatment for many rare diseases is insufficient, as are the social networks to support individuals with rare diseases and their families; furthermore, while there were already numerous days dedicated to individuals with specific diseases, there had previously not been a day for representing those affected by rare diseases. In 2009, Rare Disease Day went global as the National Organization for Rare Disorders mobilized 200 rare disease patient advocacy organizations in the United States while organizations in China, Australia, Taiwan, and Latin America also lead efforts in their respective countries to coordinate activities and promote the day.

The International Fibrodysplasia Ossificans Progressiva Association (IFOPA) is a US-based 501(c)(3) non-profit organization supporting medical research, education and communication for those afflicted by the rare genetic condition Fibrodysplasia Ossificans Progressiva (FOP). IFOPA's mission is to fund research to find a cure for FOP while supporting, connecting, and advocating for individuals with FOP and their families, and raising awareness worldwide. IFOPA is governed by a volunteer board of directors which may range in number from 9 to 15, at least one of whom must have FOP. The association's location is 1520 Clay St., Suite H2, North Kansas City, MO, 64116, part of the Kansas City, Missouri metropolitan area.

<span class="mw-page-title-main">Actelion</span> Swiss biopharmaceutical company

Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland.

<span class="mw-page-title-main">Orphan Drug Act of 1983</span> Law passed in the United States to facilitate development of orphan drugs

The Orphan Drug Act of 1983 is a law passed in the United States to facilitate development of orphan drugs—drugs for rare diseases such as Huntington's disease, myoclonus, ALS, Tourette syndrome and muscular dystrophy which affect small numbers of individuals residing in the United States.

PHACE syndrome is a medical condition involving the uncommon association between large infantile hemangiomas, usually of the face, and birth defects of the brain, heart, eyes, skin and/or arteries. PHACE is an acronym that stands for the medical names of the parts of the body it often impacts:

Marshall Summar American geneticist

Marshall L. Summar is an American physician, clinical geneticist and academic specializing in the field of genetics and rare disease. He is board-certified in pediatrics, biochemical genetics and clinical genetics. He is best known for his work in caring for children with rare genetic diseases.

<span class="mw-page-title-main">Zebra print ribbon</span> The zebra print ribbon is used for awareness of rare diseases

The zebra print ribbon is the awareness ribbon for uncommon or rare diseases and cancers including but not limited to neuroendocrine tumors, carcinoid cancer, Ehlers-Danlos Syndromes, Whipple's disease and awareness of other rare diseases, cancers and disorders.

<span class="mw-page-title-main">RareConnect</span> Social medical platform

RareConnect is a platform where patients and families share their experiences and knowledge about living with a rare disease.

References

  1. 1 2 "EURORDIS in brief". www.eurordis.org.
  2. 1 2 Nogales Espert A (2004). "[Rare diseases: a new chapter in medicine]". An R Acad Nac Med (Madr) (in Spanish). 121 (1): 139–51, discussion 151–5. PMID   15553406.
  3. Houyez F (2004). "Active involvement of patients in drug research, evaluation, and commercialization: European perspective". J Ambul Care Manage. 27 (2): 139–45. doi:10.1097/00004479-200404000-00010. PMID   15069992. S2CID   75497714.
  4. "Rare Disease Day 2018 - 28 Feb". Rare Disease Day - 28 Feb 2018.
  5. "EURORDIS Black Pearl Awards". EURORDIS Black Pearl Awards - 05 March 2024.
  6. "Canadian Organization for Rare Disorders". www.raredisorders.ca.